Janux Therapeutics (NASDAQ:JANX) Coverage Initiated at Jonestrading

Investment analysts at Jonestrading began coverage on shares of Janux Therapeutics (NASDAQ:JANX) in a research note issued to investors on Tuesday, Benzinga reports. The brokerage set a “buy” rating and a $70.00 price target on the stock. Jonestrading’s price objective points to a potential upside of 45.95% from the company’s previous close.

JANX has been the subject of a number of other research reports. Bank of America boosted their price objective on shares of Janux Therapeutics from $24.00 to $48.00 and gave the company a “buy” rating in a research report on Wednesday, March 13th. William Blair reissued an “outperform” rating on shares of Janux Therapeutics in a research report on Tuesday, February 27th. Wedbush reissued an “outperform” rating and set a $53.00 price objective on shares of Janux Therapeutics in a research report on Monday, March 11th. Cantor Fitzgerald initiated coverage on shares of Janux Therapeutics in a research report on Wednesday, March 20th. They set an “overweight” rating and a $100.00 price objective for the company. Finally, BTIG Research initiated coverage on shares of Janux Therapeutics in a report on Thursday, March 21st. They issued a “buy” rating and a $62.00 target price for the company. Seven research analysts have rated the stock with a buy rating, According to MarketBeat, the stock has an average rating of “Buy” and a consensus target price of $61.33.

Janux Therapeutics Trading Down 5.1 %

NASDAQ:JANX opened at $47.96 on Tuesday. Janux Therapeutics has a 12 month low of $5.65 and a 12 month high of $58.69. The company has a market cap of $2.48 billion, a PE ratio of -35.79 and a beta of 4.18. The company has a 50 day simple moving average of $33.62 and a two-hundred day simple moving average of $17.61.

Janux Therapeutics (NASDAQ:JANX) last posted its earnings results on Friday, March 8th. The company reported ($0.25) EPS for the quarter, topping analysts’ consensus estimates of ($0.37) by $0.12. Janux Therapeutics had a negative net margin of 721.18% and a negative return on equity of 17.88%. The business had revenue of $2.46 million during the quarter, compared to the consensus estimate of $0.98 million. Research analysts forecast that Janux Therapeutics will post -1.41 earnings per share for the current year.

Institutional Trading of Janux Therapeutics

Hedge funds have recently bought and sold shares of the stock. Nisa Investment Advisors LLC lifted its stake in Janux Therapeutics by 10,740.0% in the 4th quarter. Nisa Investment Advisors LLC now owns 2,710 shares of the company’s stock worth $29,000 after purchasing an additional 2,685 shares in the last quarter. Tower Research Capital LLC TRC lifted its stake in Janux Therapeutics by 149.4% in the 1st quarter. Tower Research Capital LLC TRC now owns 3,344 shares of the company’s stock worth $40,000 after purchasing an additional 2,003 shares in the last quarter. Barclays PLC raised its position in shares of Janux Therapeutics by 533.0% during the 4th quarter. Barclays PLC now owns 4,608 shares of the company’s stock valued at $61,000 after buying an additional 3,880 shares in the last quarter. China Universal Asset Management Co. Ltd. purchased a new stake in shares of Janux Therapeutics during the 4th quarter valued at about $57,000. Finally, Citigroup Inc. raised its position in shares of Janux Therapeutics by 935.2% during the 2nd quarter. Citigroup Inc. now owns 5,787 shares of the company’s stock valued at $69,000 after buying an additional 5,228 shares in the last quarter. Hedge funds and other institutional investors own 75.39% of the company’s stock.

About Janux Therapeutics

Janux Therapeutics, Inc, a clinical stage biopharmaceutical company, develops immunotherapies based on Tumor Activated T Cell Engagers (TRACTr) and Tumor Activated Immunomodulators (TRACIr) platforms technology to treat patients suffering from cancer. The company's clinical candidates comprise JANX007, a prostate-specific membrane antigen or PSMA-TRACTr, which is in Phase 1 clinical trial in adults for the treatment of metastatic castration-resistant prostate cancer (mCRPC) and the vasculature of other tumors; and JANX008, an epidermal growth factor receptor or EGFR-TRACTr that is in Phase 1 clinical trial for the treatment of multiple solid cancers, including colorectal cancer, squamous cell carcinoma of the head and neck, non-small cell lung cancer, and renal cell carcinoma.